Science News
from research organizations

Cardiovascular disease: New stent in clinical trials

Date:
February 9, 2015
Source:
Rutgers' Office of Research and Economic Development
Summary:
A new stent for cardiovascular disease has been implanted in patients for the first time. The drug-eluting stent is made from a tyrosine-based polymer that is visible using X-ray, aiding cardiologists implanting the device. The polymer also is fully bioresorbable.
Share:
FULL STORY

A new stent for treating cardiovascular disease that incorporates a polymer invented at Rutgers, The State University of New Jersey, has been implanted in patients for the first time.

The device, called Fantom™, is a drug-eluting scaffold being developed by REVA Medical Inc. of San Diego. The scaffold, or stent, is made from a unique formulation from a tyrosine-based polymer family invented by Joachim Kohn, Rutgers Board of Governors Professor of Chemistry. The company signed the initial licensing agreement with Rutgers in 2004 for the polymer family.

The polymer is a major step forward because the stent made from the material is fully visible using X-ray, which is extremely useful to interventional cardiologists when they are implanting the device. The polymer also is fully bioresorbable, meaning that it dissolves completely over time, which is an advantage particularly for younger patients.

The first Fantom implants were done at Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil, where REVA Senior Vice President of Clinical and Regulatory Affairs Jeff Anderson was present.

"During these first procedures, the unique features of the Fantom scaffold were evident," Anderson said. "The scaffold was easily delivered and the procedure was aided by the visibility of the scaffold under X-ray, a feature that we believe provides physicians with a valuable tool for confirming proper placement during implant."

This is a major step forward toward introducing a valuable new therapeutic tool that has the potential to help many patients worldwide," Kohn said. Kohn launched a company, TYRX Inc., in his lab 16 years ago to commercialize his patented polymer technologies in implantable medical devices. Now located in Monmouth Junction, N.J., TYRX was purchased last year by Medtronic, a global corporation, for more than $160 million.

As the founding director of the New Jersey Center for Biomaterials, Kohn has participated in the establishment of other medical device companies and has gained significant experience in academia-industry licensing negotiations. He holds 45 U.S. patents, is a Fellow of the National Academy of Inventors and twice has received the Thomas Alva Edison Patent Award. He is principal investigator of several federally funded R&D programs including the Armed Forces Institute for Regenerative Medicine. Since 1997, Kohn has received over $75 million in research support from federal and state government, private corporations and foundations.

Kohn's research focuses on new ways to develop biomaterials for specific applications, particularly tissue engineering, regenerative medicine and drug delivery, using combinatorial and computational methods. Kohn led a team of scientists who discovered a polymer optimized for fully degradable cardiovascular stents, which are being tested in clinical trials. His approach was used to develop optimized polymers for ophthalmic applications and orthopedic applications.


Story Source:

Materials provided by Rutgers' Office of Research and Economic Development. Note: Content may be edited for style and length.


Cite This Page:

Rutgers' Office of Research and Economic Development. "Cardiovascular disease: New stent in clinical trials." ScienceDaily. ScienceDaily, 9 February 2015. <www.sciencedaily.com/releases/2015/02/150209094827.htm>.
Rutgers' Office of Research and Economic Development. (2015, February 9). Cardiovascular disease: New stent in clinical trials. ScienceDaily. Retrieved May 23, 2017 from www.sciencedaily.com/releases/2015/02/150209094827.htm
Rutgers' Office of Research and Economic Development. "Cardiovascular disease: New stent in clinical trials." ScienceDaily. www.sciencedaily.com/releases/2015/02/150209094827.htm (accessed May 23, 2017).

RELATED STORIES